(CercleFinance.com) – Onxep rose by more than 4% on the stock market on Wednesday after the publication of data confirming the relevance of the association of its compound AsiDNA with PARP inhibitors.
During a presentation at the ESMO Targeted Anticancer Therapies congress, the biotechnology company unveiled new preclinical data confirming the relevance of this association.
Onxeo recalls that PARP inhibitors show no efficacy, or very limited efficacy, in tumors exhibiting active homologous recombination repair, hence the need to combine them with AsiDNA to overcome intrinsic or acquired resistance in a clinical situation.
Through its decoy mechanism, AsiDNA results in distinctive antitumor properties, including the ability to prevent or abrogate tumor resistance to targeted therapies such as PARP inhibitors.
The compound is currently undergoing clinical studies in combination in hard-to-treat solid tumors.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
